Robin Filshie

Author PubWeight™ 11.51^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).	Blood	2012	2.21
2	Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.	Blood	2008	1.64
3	High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.	Leuk Lymphoma	2010	1.64
4	Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.	Blood	2004	1.57
5	Delayed-onset neutropenia associated with rituximab therapy.	Br J Haematol	2003	1.22
6	Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.	J Clin Oncol	2007	1.10
7	Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone.	Leuk Lymphoma	2007	0.85
8	Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.	Cancer	2007	0.81
9	Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma.	Leuk Lymphoma	2015	0.78
10	An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.	Leuk Lymphoma	2014	0.75